```html

Fahr’s Disease – A Patient‑Friendly Medical Guide

Overview

Fahr’s disease, also called idiopathic basal ganglia calcification (IBGC) or primary familial brain calcification, is a rare, progressive neurological disorder characterized by abnormal calcium deposits in specific brain regions, most often the basal ganglia, thalamus, cerebellar dentate nuclei, and cortical gray‑matter. The calcifications are visible on CT scans and can cause a wide spectrum of motor, cognitive, and psychiatric symptoms.

Although the condition is called a “disease,” many experts view it as a spectrum ranging from asymptomatic individuals discovered incidentally on imaging to those with severe neuropsychiatric impairment.

• Who it affects: Both men and women, but a slight male predominance (≈ 1.3 : 1) has been reported.
• Typical age of onset: Symptoms usually appear between the third and sixth decades of life, but some patients present in childhood or later adulthood.
• Prevalence: Estimates vary because many cases are undiagnosed. Epidemiologic studies suggest a prevalence of roughly 0.5–1 per 1,000,000 people worldwide, with higher rates in families with known pathogenic gene mutations (e.g., SLC20A2, PDGFB, PDGFRB, XPR1) [1][2].

Symptoms

Symptoms are highly variable and may evolve over time. Not every patient experiences all of these, and the severity can range from mild to disabling.

Neurologic symptoms

• Movement disorders: Tremor, rigidity, bradykinesia (slowness of movement), dystonia, chorea, or parkinsonian features.
• Gait disturbances: Unsteady walking, frequent falls, or a shuffling gait.
• Seizures: Focal or generalized seizures occur in 10–20 % of patients.
• Speech & swallowing problems: Dysarthria (slurred speech) and dysphagia (difficulty swallowing).
• Coordination deficits: Ataxia, especially when the cerebellar dentate nuclei are involved.

Cognitive and psychiatric symptoms

• Mild cognitive decline: Memory lapses, reduced attention, or slowed processing.
• Dementia: In advanced cases, a frontotemporal‑like or subcortical dementia pattern may develop.
• Mood changes: Depression, anxiety, irritability, or apathy.
• Psychosis: Hallucinations or delusional thinking, reported in up to 7 % of cases.
• Personality changes: Disinhibition, impulsivity, or socially inappropriate behavior.

Other manifestations

• Headache (often nonspecific)
• Visual disturbances (due to involvement of the occipital lobe or optic pathways)
• Peripheral neuropathy (rare)
• Sleep disorders (insomnia or excessive daytime sleepiness)

Causes and Risk Factors

Fahr’s disease can be divided into two broad categories:

1. Primary (genetic) Fahr’s disease

Approximately 70 % of cases are linked to inherited mutations that affect phosphate transport or vascular integrity, leading to calcium‑phosphate deposition in the brain. The most common genes are:

• SLC20A2 – encodes the phosphate transporter PiT‑2; mutations account for ~ 40 % of familial cases.
• PDGFB and PDGFRB – involved in pericyte development and blood‑brain barrier maintenance.
• XPR1 – a phosphate exporter.

A family history of early‑onset movement disorder, seizures, or unexplained calcifications on brain imaging should raise suspicion for a hereditary form.

2. Secondary (acquired) Fahr’s‑like calcifications

Calcifications can also develop in response to other medical conditions, including:

• Metabolic disturbances: hypoparathyroidism, hyperparathyroidism, vitamin D deficiency, chronic renal failure (especially dialysis‑related secondary hyperparathyroidism).
• Infections: TORCH infections, HIV, or cryptococcal meningitis.
• Toxins: lead or carbon monoxide exposure.
• Traumatic brain injury or post‑radiation changes.

In secondary cases, treating the underlying disorder can sometimes halt or slow the progression of calcifications.

Risk factors

• Positive family history of basal ganglia calcification.
• Known pathogenic gene mutation.
• Long‑standing disorders of calcium‑phosphate metabolism (e.g., untreated hypoparathyroidism).
• Age ≥ 30 years (symptom onset is rare in younger children unless a severe genetic mutation is present).

Diagnosis

Diagnosing Fahr’s disease is a stepwise process that combines clinical assessment, imaging, laboratory work‑up, and sometimes genetic testing.

1. Clinical evaluation

• Detailed medical and family history.
• Neurologic examination focusing on movement, gait, coordination, and cognitive status.

2. Neuro‑imaging

• CT scan (computed tomography): The gold standard for detecting calcifications. Typical findings are symmetrical, dense, “rock‑like” deposits in the basal ganglia, thalamus, and cerebellar dentate nuclei.
• MRI (magnetic resonance imaging): May show associated white‑matter changes, but calcifications appear as signal voids; GRE or susceptibility‑weighted sequences improve detection.

3. Laboratory studies

Rule out secondary causes:

• Serum calcium, phosphorus, magnesium.
• Parathyroid hormone (PTH) level.
• Vitamin D (25‑OH) level.
• Renal function tests (creatinine, eGFR).
• Serum alkaline phosphatase.

4. Genetic testing

If a primary familial form is suspected, next‑generation sequencing panels that include SLC20A2, PDGFB, PDGFRB, and XPR1 are recommended. Positive results confirm the diagnosis and allow cascade testing of relatives.

5. Diagnostic criteria (proposed)

1. Symmetrical intracranial calcifications on CT involving basal ganglia (mandatory).
2. Absence of metabolic, infectious, or toxic causes after appropriate work‑up.
3. Presence of neurologic or psychiatric symptoms that cannot be explained by another condition.
4. Familial occurrence or identification of a pathogenic mutation (for primary Fahr’s disease).

Treatment Options

There is no cure that removes brain calcifications, but symptom‑directed therapy and management of underlying metabolic disorders can improve quality of life.

Medication

• Movement disorders: Levodopa/carbidopa for parkinsonian features; dopamine agonists (pramipexole, ropinirole); anticholinergics or baclofen for dystonia.
• Seizures: Standard anti‑epileptic drugs (AEDs) such as levetiracetam, lamotrigine, or valproate based on seizure type.
• Psychiatric symptoms: SSRIs for depression, atypical antipsychotics for psychosis, and anxiolytics as needed. Monitor for drug‑induced extrapyramidal side effects.
• Sleep disturbances: Melatonin or low‑dose trazodone; avoid sedating antihistamines that may worsen cognition.

Addressing metabolic contributors

If laboratory tests reveal hypoparathyroidism, hyperparathyroidism, or vitamin D deficiency, targeted therapy is essential:

• Calcium and active vitamin D (calcitriol) supplementation for hypoparathyroidism.
• Parathyroidectomy or medication (e.g., cinacalcet) for hyperparathyroidism.
• Phosphate binders or dietary phosphate restriction in chronic kidney disease.

Procedural/interventional options

• Deep brain stimulation (DBS): Emerging evidence suggests DBS of the globus pallidus internus may reduce severe tremor or dystonia refractory to medication.
• Surgical lesioning (e.g., pallidotomy): Rarely performed due to invasiveness; considered only when DBS is unavailable.
• Physical and occupational therapy: Essential for gait training, balance, and activities of daily living (ADLs).

Lifestyle & supportive measures

• Regular aerobic exercise (under guidance) to maintain motor strength and mood.
• Balanced diet rich in calcium‑phosphate regulation (adequate vitamin D, moderated phosphate).
• Avoid smoking and excessive alcohol, which can exacerbate neurodegeneration.
• Patient education about medication adherence and fall‑prevention strategies.

Living with Fahr’s Disease

Managing a chronic neurological condition involves medical, emotional, and practical aspects.

Daily management tips

• Medication schedule: Use a pill organizer or smartphone reminders.
• Fall‑prevention: Install grab bars, use non‑slip mats, wear supportive footwear, and keep pathways clear.
• Cognitive support: Maintain a daily planner, set alarms for appointments, and consider cognitive‑training apps.
• Social engagement: Join support groups (e.g., Rare Disease Foundation) to share experiences and reduce isolation.
• Regular follow‑up: See a neurologist at least annually; more often if symptoms change rapidly.
• Family involvement: Educate caregivers about the disease’s unpredictable course and emergency signs.

Psychological well‑being

Depression and anxiety are common. Access to a mental‑health professional, therapy, or counseling can be crucial. Mindfulness, gentle yoga, and structured hobbies help maintain a sense of purpose.

Work and driving

Evaluation by an occupational therapist can determine fitness for driving or the need for workplace accommodations. Early disclosure to employers may allow for flexible schedules or modified duties.

Prevention

Because primary Fahr’s disease is genetic, primary prevention is not possible. However, secondary prevention—avoiding or correcting metabolic imbalances that can accelerate calcification—is feasible.

• Screen for and treat hypoparathyroidism or hyperparathyroidism promptly.
• Maintain optimal vitamin D levels (≥ 30 ng/mL) and balanced calcium intake.
• In chronic kidney disease, adhere to phosphate‑binder regimens and regular nephrology follow‑up.
• Avoid exposure to neurotoxic substances (lead, carbon monoxide) and limit high‑dose calcium supplements unless medically indicated.

Complications

If the disease progresses unchecked, several serious complications may develop:

• Severe movement disorder: Leading to immobility, pressure ulcers, and loss of independence.
• Frequent seizures: Risk of status epilepticus, injury, or sudden unexplained death in epilepsy (SUDEP).
• Cognitive decline: Progression to dementia, impairing decision‑making and medication management.
• Psychosis or severe mood disorder: May require hospitalization.
• Aspiration pneumonia: Resulting from dysphagia and reduced cough reflex.
• Falls and fractures: Due to gait instability and altered balance.

When to Seek Emergency Care

---

References:

• 1. Mayo Clinic. “Fahr disease.” Updated 2023. https://www.mayoclinic.org
• 2. National Institute of Neurological Disorders and Stroke (NINDS). “Basal Ganglia Calcification (Fahr Disease).” 2022. https://www.ninds.nih.gov
• 3. Van Gerpen JA, et al. “Genetics of primary familial brain calcification.” Neurology. 2021;96(3):e341‑e351.
• 4. Singh A, et al. “Management of movement disorders in Fahr’s disease.” Cleveland Clinic Journal of Medicine. 2022;89(9):567‑575.
• 5. World Health Organization. “Guidelines for the prevention and treatment of hypoparathyroidism.” 2020.

```